Savara Inc (SVRA) research
Savara Inc- Sector
- Biotechnology
- Last price
- $5.07
- As of
Savara Inc (SVRA): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-11.
As of . Source: SEC EDGAR filings for SVRA. Method and limitations.
Share the SVRA intelligence card
See SVRA live in the terminal
Track SVRA's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live SVRA terminal, freeActive signals for SVRA
- highCONSENSUS_BUY
3 tracked funds increased SVRA this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
RENAISSANCE TECHNOLOGIES LLC cut 62% of SVRA (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 95% of SVRA (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 66% of SVRA (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 95% of SVRA (2026Q2)
FREE, NO ACCOUNT
Every signal on SVRA, as it fires
You are seeing 5 of 24 signals recorded on SVRA since 2026-05-17.
The five above landed across 2 days. The other 19 were recorded on 4 other days. 19 of the 24 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in SVRA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 805111101 · 2026Q2 | $15.5M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 805111101 · 2026Q2 | $1.6M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 805111101 · 2026Q2 | $1.5M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 805111101 · 2026Q2 | $232K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, SVRA
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
SVRA against its peers
SVRA's return on equity of -58.5% ranks in the 46th percentile of 13 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | SVRA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 67.5M | n/a | 7 |
| Operating margin | n/a | -130.2% | n/a | 7 |
| Net margin | n/a | -140.3% | n/a | 7 |
| Return on equity | -58.5% | -46.8% | 46 | 13 |
Peers (16): GLUE, MLTX, CRVS, KURA, JBIO, SANA, JANX, ABUS, MNKD, LXRX, SGP, SLDB, CADL, MGTX, REPL, IMMX. Left out: ANL (period gap), OBX (no annual filing), HELP (period gap), APMD (no annual filing), SLBT (no annual filing), ODTX (no annual filing), SPTX (no annual filing), AKTS (no annual filing), IVA (period gap). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (SVRA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more SVRA signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to SVRAand get the insider, 13F, options, and confluence read in one view.